NGeneBio Sets Rights Offering First Issue Price at 1,074 KRW, 37% Discount to Market Price, Raising Major Dilution Concerns

NGeneBio has set the first issue price for its rights offering at 1,074 KRW per share.
The price represents a 25% discount from the reference price and a 37% discount from the current market price of 1,710 KRW.
Issuing 7,150,000 new shares would dilute existing shareholders by approximately 80% relative to current outstanding shares.
The final issue price will be announced on September 7, 2026, but the low first price raises significant dilution concerns.
[AI Summary]NGeneBio's rights offering will cause substantial dilution to existing shareholders. The deep discount of the first issue price exacerbates value erosion. Investors should monitor the final price and subscription results closely.